Wegovy Pill Weight Loss
Real-world study shows continued weight loss after switching to daily Wegovy pill.
Anonymous
Key Points
1
The 194 participants had switched from either injectable semaglutide—Wegovy or Ozempic—or tirzepatide—Zepbound or Mounjaro. About half had been using Novo Nordisk’s Wegovy injection and half Eli Lilly’s Zepbound; roughly 56% were women.
2
The share of participants classified as having obesity, defined as a BMI of at least 30, declined from 87.1% before the switch to 65.5% after three months.
3
In the data cited by Everyday Health, 87% of participants reported taking the oral medication daily.
4
Novo executive Martin Holst Lange said some patients may prefer pills because of needle anxiety, lifestyle or personal preference; he also cited frequent travelers who would rather not keep injections refrigerated.
5
Richard Siegel, an endocrinologist at Tufts Medical Center who was not involved in the research, said the findings were “very believable.”
Adults who switched from injectable weight-loss shots to Novo Nordisk's daily Wegovy pill continued losing weight, according to real-world data from the OCTANE study presented at a major obesity conference. Among 194 people tracked for three months, average weight loss reached 4.1%—roughly 8.8 pounds—with 40.7% shedding at least 5% of their body weight Everyday Health.
The findings highlight a growing shift in how people manage obesity: from needles to pills. About three-quarters of participants reported satisfaction with the switch, and many noted better-fitting clothes and healthier eating habits. However, the study is preliminary and cannot prove the pill itself caused the weight loss Everyday Health.
Who Switched and What Happened to Their Weight
The 194 participants had been taking either Wegovy or Ozempic injections—both contain semaglutide made by Novo Nordisk—or Zepbound and Mounjaro injections, which contain tirzepatide made by Eli Lilly Everyday Health. Roughly half used Novo's shot; half used Eli Lilly's. About 56% were women Everyday Health.
The share of people classified as having obesity dropped sharply. Before switching, 87.1% had a BMI of 30 or higher. After three months on the pill, that fell to 65.5% Everyday Health. About 87% of participants reported taking the oral medication every single day Everyday Health.
Why Patients May Prefer Pills Over Injections
Pills offer convenience that injections cannot. Novo executive Martin Holst Lange explained that some patients struggle with needle anxiety or simply prefer swallowing a tablet. Frequent travelers were another key group—they avoid keeping injections refrigerated while moving between locations Everyday Health.
The shift reflects a broader trend in weight-loss treatment. As more options emerge, patients gain flexibility in choosing what fits their lifestyle. A pill taken daily with food is simpler than managing an injection schedule for some users.
The Reality Check on These Study Results
The OCTANE findings carry important limits. The data came from medical records and patient reports collected by Ro, a telehealth company, in collaboration with Novo Nordisk. No control group existed to show that the pill specifically caused the weight loss rather than other factors Everyday Health.
Yet some experts found the results credible. Richard Siegel, an endocrinologist at Tufts Medical Center who did not participate in the research, called the findings "very believable." The three-month window is short, so longer-term data will be crucial to understand whether weight loss continues Everyday Health.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
106
Reach
125
A
AnonymousAuthor
